Interferon treatment in polycythaemia vera

Leukemia & Lymphoma
J T ReillyJ T De Wolff

Abstract

Recent studies have shown rIFN alpha to be an effective agent in the management of polycythemia vera. Red cell mass can be controlled within 6 to 12 months, eliminating the need for phlebotomy in up to 70% of cases. In addition, significant improvement in the platelet counts, iron status, pruritus scores and the degree of splenomegaly have been reported. Most patients require between 9 and 25 x 10(6)U/week, although once the disease is under control it may be possible to reduce both the dose and frequency of administration. Side-effects remain a significant problem, occurring in over 30% of patients, and may be related to the high mean age of the patients. Long-term studies are now indicated to determine if the natural history of the disease is altered and whether, in particular, the incidence of myelofibrosis and/or leukaemic transformation is reduced.

References

Feb 1, 1976·Journal of Medical Genetics·W R CenterwallL M Reeves
Oct 1, 1978·British Journal of Haematology·P R DallmanC A Finch
Nov 30, 1976·Molecular and Cellular Biochemistry·I I NikolskayaS S Debov
Oct 21, 1976·The New England Journal of Medicine·J W AdamsonL Steinmann
Apr 1, 1975·British Journal of Haematology·I Chanarin, L Szur
Apr 1, 1992·British Journal of Haematology·A F List, D C Doll
Jan 26, 1991·Lancet·J T de WolfE Vellenga
May 1, 1990·American Journal of Hematology·S NandR I Fisher
Feb 14, 1985·Nature·M Clemens
Feb 13, 1988·Lancet·H Hasselbalch
Jul 9, 1988·Lancet·F J GilesA B Mehta
Apr 1, 1987·The Journal of Clinical Investigation·R D GransteinE P Amento
Oct 1, 1988·European Journal of Haematology·E Löfvenberg, A Wahlin
Mar 1, 1986·Journal of the American Academy of Dermatology·S T Denman
Jan 1, 1987·Cancer Immunology, Immunotherapy : CII·H LudwigM Micksche
Sep 1, 1987·European Journal of Haematology·L ParmeggianiG Sokal
Jan 1, 1987·The British Journal of Dermatology·N JacksonB Boughton
Oct 1, 1985·Journal of the American Academy of Dermatology·R A Swerlick
Dec 1, 1983·Annals of Internal Medicine·M TalpazJ U Gutterman
Jul 10, 1982·British Medical Journal·H H SalemJ S Wiley
Feb 1, 1982·Archives of Internal Medicine·J K WeickJ D Goldberg
Sep 1, 1994·British Journal of Haematology·J T Reilly
Oct 1, 1994·British Journal of Haematology·J T de WolfE Vellenga
Mar 24, 1994·The New England Journal of Medicine·UNKNOWN Italian Cooperative Study Group on Chronic Myeloid LeukemiaMauro Fiacchini
Feb 1, 1994·British Journal of Haematology·C MessoraS Sacchi
Dec 1, 1993·Annals of Internal Medicine·R T Silver
Sep 1, 1993·British Journal of Haematology·R E Gale, J S Wainscoat
Aug 1, 1993·American Journal of Hematology·C FinelliS Tura

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

© 2021 Meta ULC. All rights reserved